- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
News Briefs: Global Med unveils disease management software
Global Med unveils disease management softwareGlobal Med, an application service provider focusing on medical IT and data management products, will launch DynaMetric, its new disease management software, at the National Managed Health Care Congress
Global Med unveils disease management software
Global Med, an application service provider focusing on medical IT and data management products, will launch DynaMetric, its new disease management software, at the National Managed Health Care Congress in Atlanta this month. DynaMetric tracks, collects, and compiles data on chronic diseases. Global Med of Lakewood, CO, says its first customer is a regional division of a large HMO, which plans to use the software initially to track a single chronic disease on a per-member per-month fee basis, and eventually to track up to 20 manageable chronic diseases. Global Med is providing the application through its wholly owned subsidiary, PeopleMed.com.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
